SCHEMBL2263282

SCHEMBL2263282

COC(=O)c1cccc(NC(=O)c2ccccc2Cl)c1.COC(=O)c1cccc(NC(=O)c2ccccc2F)c1

nearest known ligand 0.71

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.71
NPC1 O15118 6/20 0.71
POLB P06746 2/20 0.71
PKM P14618 1/20 0.71
ALDH1A1 P00352 3/20 0.69
L3MBTL1 Q9Y468 1/20 0.69
KMT2A Q03164 6/20 0.64
KDM4E B2RXH2 3/20 0.64
MEN1 O00255 5/20 0.61
SMN1; SMN2 Q16637 3/20 0.61
KCNK3 O14649 2/20 0.61
KCNK9 Q9NPC2 2/20 0.61
MAPT P10636 4/20 0.60
HPGD P15428 1/20 0.60
CYP1A2 P05177 1/20 0.54
CYP3A4 P08684 1/20 0.54
CYP2D6 P10635 1/20 0.54
CYP2C9 P11712 1/20 0.54
CYP2C19 P33261 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1818135 0.93 ALDH1A1 (0.80) RAB9ANPC1POLBPKMALDH1A1
SCHEMBL1813249 0.93 RAB9A (0.81) RAB9ANPC1POLBPKMALDH1A1
SCHEMBL6819638 0.85 ALDH1A1 (0.67) RAB9ANPC1POLBALDH1A1L3MBTL1
SCHEMBL3610429 0.84 ALDH1A1 (0.65) RAB9ANPC1POLBPKMALDH1A1
SCHEMBL14096355 0.81 ALDH1A1 (0.80) RAB9ANPC1POLBPKMALDH1A1
SCHEMBL2011651 0.81 RAB9A (0.77) RAB9ANPC1POLBPKMALDH1A1
SCHEMBL13878279 0.80 NPC1 (0.73) RAB9ANPC1ALDH1A1L3MBTL1KMT2A
SCHEMBL2009483 0.79 SMN1; SMN2 (0.74) RAB9ANPC1ALDH1A1L3MBTL1KMT2A
SCHEMBL3592038 0.78 RAB9A (0.78) RAB9ANPC1POLBPKMALDH1A1
SCHEMBL1811041 0.78 KCNK3 (0.81) RAB9ANPC1POLBALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110201603-A1 Novel Acylaminobenzamide Derivatives BAYER CROPSCIENCE AG (DE) 2011-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201603-A1 Novel Acylaminobenzamide Derivatives KCNB1, KCNA5, KCNA7 RAB9A 742/4885NPC1 3104/4885POLB 1730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.